why choose us

First received: September 01, 2023

Clinical Trial: Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: PD-1 Refractory Advanced Melanoma

Study Type: INTERVENTIONAL


Official Title: Randomized Phase II Study of Pembrolizumab/Lenvatinib With and Without Responder-derived FMT (R-FMT) in Relapsed/Refractory Melanoma

Brief Summary: In this is a randomized phase II study the addition of R-FMT to pembrolizumab /lenvatinib in PD-1 R/R melanoma will be evaluated over a 104-week period in patients with anti-PD-1 R/R disease.Patients with PD-1 refractory advanced melanoma are eligible to enroll, excluding patients with prior lenvatinib (or other TKI) exposure.Intestinal microbiome composition mediates response to anti-PD-1 by affecting systemic inflammatory tone.

Read more